Stereoselective flunoxaprofen-S-acyl-glutathione thioester formation mediated by acyl-CoA formation in rat hepatocytes.
Flunoxaprofen (FLX) is a chiral nonsteroidal anti-inflammatory drug that was withdrawn from clinical use because of concerns of potential hepatotoxicity. FLX undergoes highly stereoselective chiral inversion mediated through the FLX-S-acyl-CoA thioester (FLX-CoA) in favor of the (R)-(-)-isomer. Acyl-CoA thioester derivatives of acidic drugs are chemically reactive species that are known to transacylate protein nucleophiles and glutathione (GSH). In this study, we investigated the relationship between the stereoselective metabolism of (R)-(-)- and (S)-(+)-FLX to FLX-CoA and the subsequent transacylation of GSH forming FLX-S-acyl-glutathione (FLX-SG) in incubations with rat hepatocytes in suspension. Thus, when hepatocytes (2 million cells/ml) were treated with (R)-(-)- or (S)-(+)-FLX (100 microM), both FLX-CoA and FLX-SG were detected by sensitive liquid chromatography-tandem mass spectrometry techniques. However, these derivatives were observed primarily from (R)-(-)-FLX incubation extracts, for which the formation rates of FLX-CoA and FLX-SG were rapid, reaching maximum concentrations of 42 and 2.8 nM, respectively, after 6 min of incubation. Incubations with (S)-(+)-FLX over 60 min displayed 8.1 and 2.7% as much FLX-CoA and FLX-SG area under the concentration versus time curves, respectively, compared with corresponding incubations with (R)-(-)-FLX. Coincubation of lauric acid (1000 microM) with (R)-(-)-FLX (10 microM) led to the complete inhibition of FLX-CoA formation and a 98% inhibition of FLX-SG formation. Reaction of authentic (R,S)-FLX-CoA (2 microM) with GSH (10 mM) in buffer (pH 7.4, 37 degrees C) showed the quantitative formation of FLX-SG after 3 h of incubation. Together, these results demonstrate the stereoselective transacylation of GSH in hepatocyte incubations containing (R)-(-)-FLX, which is consistent with bioactivation by stereoselective (R)-FLX-CoA formation.
Pharmacokinetics and Drug Metabolism, Amgen Inc., South San Francisco, CA 94080, USA. grillo@amgen.com
Mark P
MP
Grillo
Jill C M
JC
Wait
Michelle
M
Tadano Lohr
Smriti
S
Khera
Leslie Z
LZ
Benet
D000214:Acyl Coenzyme A / Q000096:biosynthesis* / Q000378:metabolism; D000215:Acylation; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000378:metabolism / Q000493:pharmacokinetics; D001583:Benzoxazoles / Q000737:chemistry* / Q000378:metabolism* / Q000493:pharmacokinetics; D055162:Biocatalysis; D001711:Biotransformation; D001892:Camphanes / Q000494:pharmacology; D002851:Chromatography, High Pressure Liquid; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004952:Esters / Q000378:metabolism*; D020723:Glucuronic Acid / Q000378:metabolism; D005978:Glutathione / Q000737:chemistry / Q000378:metabolism*; D022781:Hepatocytes / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D007052:Ibuprofen / Q000378:metabolism; D007700:Kinetics; D007850:Lauric Acids / Q000494:pharmacology; D008297:Male; D015394:Molecular Structure; D051381:Rats; D017207:Rats, Sprague-Dawley; D013237:Stereoisomerism; D013438:Sulfhydryl Compounds / Q000378:metabolism*; D053719:Tandem Mass Spectrometry
D000214:Acyl Coenzyme A; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001583:Benzoxazoles; D001892:Camphanes; D004791:Enzyme Inhibitors; D004952:Esters; D007850:Lauric Acids; D013438:Sulfhydryl Compounds; C030358:lauric acid; D020723:Glucuronic Acid; D005978:Glutathione; C022871:isoborneol; C045356:flunoxaprofen; D007052:Ibuprofen